Patent directory · USPTO A61K / A61P
Patents matching “The Regents of the University of California”
3,494 pharma patents match "The Regents of the University of California" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 3,494 pharmaceutical patents matching "The Regents of the University of California" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 10980755
LRH-1 modulators
granted -
US 10982231
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10980848
Antimicrobial therapy
granted -
US 10982232
Diterpene synthases and their use for production of diterpenes
granted -
US 10975158
CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
granted -
US 10975355
Controlled induction of human pancreatic progenitors produces functional beta-like cells
granted -
US 10975166
Inhibitory antibodies against MMP-14
granted -
US 10968203
Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders
granted -
US 10959984
Methods for treating cancer with RORγ inhibitors
granted -
US 10960071
Platform for generating safe cell therapeutics
granted -
US 10961282
Variant adeno-associated viruses and methods of using
granted -
US 10954304
Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy
granted -
US 10952970
Use of vitelline protein B as a microencapsulating additive
granted -
US 10953098
Chemical structures for localized delivery of therapeutic agents
granted -
US 10952980
GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes
granted -
US 10947302
Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them
granted -
US 10947507
Platform for generating safe cell therapeutics
granted -
US 10946106
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
granted -
US 10947207
GP130 modulators
granted -
US 10940214
Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord
granted -
US 10934334
Peptides for angiogenic therapy
granted -
US 10934332
Structure-based peptide inhibitors that target the Tau VQIINK fibrillization segment
granted -
US 10934527
Generation of lineage-restricted progenitor cells from differentiated cells
granted -
US 10934264
Amyloid targeting agents and methods of using the same
granted